BioHarvest posts higher Q2 revenue, secures manufacturing deal for premium fragrance compound
BioHarvest Sciences (BHST) reported Q2 revenue of $8.8M, up 3.8% y/y, with net loss of $3.7M ($0.17/sh) versus $4.1M ($0.24/sh) a year earlier. Operating expenses rose to $7.6M. Cash and equivalents plus deposits were $16.25M at June 30. It tightened CDMO guidance to $4M-$5M and cut VINIA guidance to $33M-$35M, and signed a UAE customer deal for 20 tons of a fragrance ingredient starting as early as H1 2027.
How this was made
The 30-second read
Why it matters
The company combined a Q2 update with full-year guidance revisions and a new scaled manufacturing agreement, changing the expected revenue mix toward CDMO manufacturing while acknowledging continued losses.
Market read
Traders can reassess BioHarvest’s forward revenue trajectory due to tighter CDMO guidance and a new production agreement, while monitoring cash and loss trajectory given widened adjusted EBITDA loss and expected consolidated EBITDA losses.
What to watch
VINIA D2C revenue guidance was lowered materially (from $38M-$42M to $33M-$35M), and adjusted EBITDA loss widened, which could dominate the market reaction if investors focus on near-term profitability rather than long-dated manufacturing ramp.
Background
BioHarvest is transitioning from proving its Botanical Synthesis technology across industries to converting top opportunities into recurring manufacturing revenue, royalties, and sustainable profitability.
Ticker impact
BioHarvest reported Q2 revenue of $8.8M, narrowed net loss, tightened CDMO guidance, and announced a UAE manufacturing deal for a rare fragrance ingredient.
Likely modest positive bias for the stock on the guidance and contract visibility, tempered by continued cash burn and the VINIA revenue reset.
The article discloses multiple primary catalysts: Q2 financials, revised full-year ranges, and a new production agreement (20 tons starting as early as H1 2027). However, it also signals ongoing profitability pressure via widened adjusted EBITDA loss and expected consolidated EBITDA losses.
Market effects
Supports the narrative that CDMO and botanical synthesis platforms can shift toward recurring manufacturing revenue, potentially improving sentiment toward plant-based ingredient and CDMO peers.
UAE-based customer deal highlights Middle East demand for premium fragrance inputs, which may influence regional supply-chain expectations.
Scaled production of a high-value fragrance ingredient points to ongoing global luxury fragrance demand and supply constraints, relevant to upstream specialty ingredient markets.
Counterpoint
The manufacturing deal starts limited production as early as H1 2027, so near-term earnings impact may be limited versus the magnitude of ongoing EBITDA losses and higher operating expenses.
Key entities
- companyBioHarvest Sciences Inc
Reported Q2 results, revised full-year guidance, and announced a UAE manufacturing deal for a rare fragrance ingredient.
- government_agencyIsrael Innovation Authority
Provided a $1.4M grant in July to support predictive AI and factory automation.
- companyTate & Lyle
Expanded a sweetener development collaboration covering multiple plant-based molecules.
